Core Insights - TuoXin Pharmaceutical experienced a stock decline of 0.89% on November 6, with a trading volume of 59.96 million yuan [1] - The company reported a financing net buy of -1.90 million yuan on the same day, indicating more financing repayments than purchases [1] - As of November 6, the total financing and securities lending balance for TuoXin Pharmaceutical was 147 million yuan, representing 3.62% of its market capitalization [1] Financing Summary - On November 6, TuoXin Pharmaceutical had a financing buy amount of 4.42 million yuan, while the current financing balance stands at 147 million yuan, which is above the 50th percentile level over the past year [1] - The company repaid 700 shares of securities lending and sold 200 shares on the same day, with a selling amount of 6,424 yuan [1] - The securities lending balance is 122,100 yuan, which is below the 20th percentile level over the past year, indicating a low position [1] Business Performance - As of October 31, TuoXin Pharmaceutical had 18,700 shareholders, an increase of 3.48% from the previous period, with an average of 4,839 circulating shares per shareholder, a decrease of 3.36% [2] - For the period from January to September 2025, the company reported a revenue of 272 million yuan, a year-on-year decrease of 16.64%, and a net profit attributable to the parent company of -30.16 million yuan, a significant decrease of 1,036.53% [2] - Since its A-share listing, TuoXin Pharmaceutical has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2] Company Overview - TuoXin Pharmaceutical Group Co., Ltd. is located in Xinxiang City, Henan Province, and was established on February 3, 2005, with its listing date on October 27, 2021 [1] - The company's main business involves the research, production, and sales of chemical synthesis and biological fermentation nucleoside (acid) raw materials and pharmaceutical intermediates [1] - The revenue composition of the company includes 62.74% from pharmaceutical intermediates, 37.03% from raw materials, and 0.23% from other sources [1]